Ranbaxy now faces product bans in Europe

Six years after the FDA banned products from a Ranbaxy Laboratories plant in Dewas, India, the European Commission and Germany have restricted imports of sterile drugs from the facility. Regulators have banned Ranbaxy's injectable versions of its cephalosporin antibiotics following an inspection earlier this year of the company's plant in central India. The Dewas plant was one of two Ranbaxy facilities the FDA banned in 2008 when issues were first brought to its attention by a whistleblower. The Indian drugmaker paid $500 million in penalties last year to settle litigation with the Justice Department tied to shortcomings found at the facilities, but in the last couple of years, the FDA has banned two more Ranbaxy plants for similar issues. Story

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.